Filtered By:
Specialty: Infectious Diseases
Infectious Disease: COVID-19
This page shows you your search results in order of date.
Order by Relevance | Date
Total 65 results found since Jan 2013.
Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: a single-institutional study in Germany
CONCLUSIONS: It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.PMID:36892192 | DOI:10.1111/ddg.14987
Source: Herpes - March 9, 2023 Category: Infectious Diseases Authors: Rosi Wang Sonja Mathes Carla Claussen Tilo Biedermann Knut Brockow Source Type: research
Impact of collaborative physician-pharmacist stewardship strategies on prophylactic antibiotic practices: a quasi-experimental study
ConclusionsThis study shows that optimization of SAP practices is achievable within a proactive multidisciplinary approach including real-time pharmaceutical interventions in the operating area and in the care units practicing SAP.
Source: Antimicrobial Resistance and Infection Control - July 26, 2022 Category: Infectious Diseases Source Type: research
Fauci Tests Positive for COVID-19 Fauci Tests Positive for COVID-19
Fauci, who is also the director of the National Institute of Allergy and Infectious Diseases, tested positive for COVID on a rapid antigen test.WebMD Health News
Source: Medscape Infectious Diseases Headlines - June 15, 2022 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Fauci: COVID-19 Is Here to Stay, but We Can Control It
(MedPage Today) -- Though it would be next to impossible to eradicate SARS-CoV-2, it is fully feasible to control it, said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), during a virtual event...
Source: MedPage Today Infectious Disease - April 29, 2022 Category: Infectious Diseases Source Type: news
Inert Ingredient Tied to Allergic Reactions to COVID-19 Vaccines Inert Ingredient Tied to Allergic Reactions to COVID-19 Vaccines
Immunological testing points to an inert vaccine component as a potential cause of mRNA vaccine allergic reactions, which may be mediated through immunoglobulin G rather than IgE.Medscape Medical News
Source: Medscape Infectious Diseases Headlines - September 28, 2021 Category: Infectious Diseases Tags: Allergy & Clinical Immunology News Source Type: news
Even Highly Allergic Adults Unlikely to React to COVID-19 Vaccine Even Highly Allergic Adults Unlikely to React to COVID-19 Vaccine
In the few individuals who did experience allergic reactions to the Pfizer-BioNTech COVID-19 vaccine in an Israeli study, symptoms resolved within 2 to 6 hours, and no hospitalization was necessary.Medscape Medical News
Source: Medscape Infectious Diseases Headlines - August 31, 2021 Category: Infectious Diseases Tags: Allergy & Clinical Immunology News Source Type: news
Children's National Hospital and NIAID launch study on long-term impacts of COVID-19 and MIS-C
(Children's National Hospital) Up to 2,000 children and young adults will be enrolled in a study from Children's National Hospital in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) that will examine the long-term effects of COVID-19 and multisystem inflammatory syndrome in children (MIS-C) after these patients have recovered from a COVID-19 infection.
Source: EurekAlert! - Infectious and Emerging Diseases - July 20, 2021 Category: Infectious Diseases Source Type: news
Adjuvant developed with NIH funding enhances efficacy of India's COVID-19 vaccine
(NIH/National Institute of Allergy and Infectious Diseases) An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Source: EurekAlert! - Infectious and Emerging Diseases - June 29, 2021 Category: Infectious Diseases Source Type: news
NIH begins study of COVID-19 vaccination during pregnancy and postpartum
(NIH/National Institute of Allergy and Infectious Diseases) A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum people. Researchers will measure the development and durability of antibodies against SARS-CoV-2, the virus that causes COVID-19, in people vaccinated during pregnancy or the first two postpartum months. Researchers also will assess vaccine safety and evaluate the transfer of vaccine-induced antibodies to infants across the placenta and through breast milk.
Source: EurekAlert! - Infectious and Emerging Diseases - June 23, 2021 Category: Infectious Diseases Source Type: news
Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, is leading and funding the study through the Infectious Diseases Clinical Research Consortium, a clinical trials network.
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2021 Category: Infectious Diseases Source Type: news
COVID-19 vaccine responses to be studied in people with immune deficits
(NIH/National Institute of Allergy and Infectious Diseases) A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions.
Source: EurekAlert! - Infectious and Emerging Diseases - April 23, 2021 Category: Infectious Diseases Source Type: news
Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins
(NIH/National Institute of Allergy and Infectious Diseases) A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure. The trial is supported by two components of the NIH, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI), and is part of the NIH Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) public-private partnership.
Source: EurekAlert! - Infectious and Emerging Diseases - April 22, 2021 Category: Infectious Diseases Source Type: news
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. The trial, ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The therapeutic was developed by SAB Biotherapeutics, Inc. (Sioux Falls, South Dakota).
Source: EurekAlert! - Infectious and Emerging Diseases - April 21, 2021 Category: Infectious Diseases Source Type: news
Updated advice for safe COVID-19 vaccination in people with high-risk allergy histories
(Massachusetts General Hospital) Experts have narrowed the group of individuals with prior allergies who should see an allergist before receiving a COVID-19 vaccine. Allergy evaluation with skin testing prior to COVID-19 vaccination is rarely needed.
Source: EurekAlert! - Infectious and Emerging Diseases - April 19, 2021 Category: Infectious Diseases Source Type: news
Experimental antiviral for COVID-19 effective in hamster study
(NIH/National Institute of Allergy and Infectious Diseases) The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from NIH scientists. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news
